Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133872 · ClinicalTrials.gov registry record · Phase 2
Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02133872 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 34 participants.
The verdict
NCT02133872, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
Hypertension (HTN) is the single most prevalent risk factor for cardiovascular disease, diabetes, obesity and metabolic syndrome. Recent American Heart Association (AHA) statistics indicate that one-third of all adults in the United States of America suffer from HTN. Despite advances in life style modification and multi-drug therapies, 20-30% of all hypertensive patients remain resistant. These individuals exhibit autonomic dysregulation due to elevated sympathetic activity and norepinephrine spillover, and low parasympathetic activity. It is generally accepted that this uncontrolled, resistant HTN is primarily "neurogenic" in origin, involving over activity of the sympathetic nervous system that initiates and sustains HTN. A surgical approach such as the recently developed "Simplicity Catheter" assisted renal denervation remains one of the few options available to these patients. Thus, a mechanism-based breakthrough is imperative to develop novel strategies to prevent and perhaps eventually cure neurogenic hypertension (NH). This study is designed to evaluate a low and high dose of minocycline to test the hypothesis that minocycline treatment would produce antihypertensive effects in drug-resistant neurogenic hypertensive individuals. Minocycline has been selected because of its demonstrated effects on inhibiting microglial activation and its ability to penetrate the blood brain barrier. There is no other compound available that is safer and displays specificity better than Minocycline in inhibiting microglial activation. Thus, the potential therapeutic benefits of this inexpensive, well tolerated, already FDA-approved drug that has minimal side effects would be enormous.
Interventions
- DRUG Minocycline 50mg/d
- DRUG Minocycline 100mg/d
- DEVICE Minocycline 200mg/d
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02133872
The ClinicalTrials.gov registry entry for NCT02133872 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Minocycline 50mg/d is the first listed.
NCT02133872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02133872 about?
NCT02133872 is a clinical study titled "Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients". Hypertension (HTN) is the single most prevalent risk factor for cardiovascular disease, diabetes, obesity and metabolic syndrome. Recent American Heart Association (AHA) statistics indicate that one-third of all adults in the United States of America suffer from HTN. Despite advances in life style m...
What is the current status of trial NCT02133872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2014-10. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT02133872?
The interventions under investigation include: Minocycline 50mg/d (DRUG), Minocycline 100mg/d (DRUG), Minocycline 200mg/d (DEVICE).
Who is sponsoring clinical trial NCT02133872?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.